The role of epigenetic changes with special focus on histone modifying enzymes in breast cancer is explored. Blending both epigenetic anomalies and genome instability is suggested as useful tool for breast cancer diagnosis. A basic understanding of HAT and HDACs families is required in designing potential cancer therapeutics.